Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Cara Therapeutics Inc. (CARA)

16.4   0.05 (0.31%) 12-12 16:00
Open: 16.46 Pre. Close: 16.35
High: 16.7 Low: 16.2
Volume: 572,177 Market Cap: 766M
Cara Therapeutics Inc is an emerging biotechnology company. It is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.939 - 17.023 17.023 - 17.09
Low: 16.042 - 16.154 16.154 - 16.245
Close: 16.194 - 16.363 16.363 - 16.499

Technical analysis

as of: 2019-12-12 3:58:56 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 26.33     One year: 31.15
Support: Support1: 15.86    Support2: 13.20
Resistance: Resistance1: 22.54    Resistance2: 26.67
Pivot: 20.46
Moving Average: MA(5): 16.53     MA(20): 20.78
MA(100): 21.43     MA(250): 19.60
MACD: MACD(12,26): -1.33     Signal(9): -0.56
Stochastic oscillator: %K(14,3): 6.28     %D(3): 6.41
RSI: RSI(14): 33.45
52-week: High: 27.55  Low: 12.19  Change(%): 16.7
Average Vol(K): 3-Month: 71839  10-Days: 146010

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CARA has closed above bottom band by 25.8%. Bollinger Bands are 271.8% wider than normal. The large width of the bands suggest high volatility as compared to CARA's normal range. The bands have been in this wide range for 11 bars. This is a sign that the current trend might continue.

Headline News

2019-12-06
Enteris BioPharma's Licensing Partner, Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for the Treatment of Pruritus in Patients with Advanced Chronic Kidney Disease (CKD)
BOONTON, N.J., Dec. 6, 2019 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB), congratulates Cara Therapeutics on the…

2019-12-04
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 46.68
Shares Float (M) 42.45
% Held by Insiders 2.87
% Held by Institutions 62.37
Shares Short (K) 5630
Shares Short P. Month (K)

Stock Financials

EPS -2.410
Book Value (p.s.) 4.540
PEG Ratio
Profit Margin
Operating Margin -495.92
Return on Assets (ttm) -27.2
Return on Equity (ttm) -54.5
Qtrly Rev. Growth 14.3
Gross Profit (p.s.) -1.329
Sales Per Share
EBITDA (p.s.) -2.217
Qtrly Earnings Growth
Operating Cash Flow (M) -102.42
Levered Free Cash Flow (M) -51.63

Stock Valuations

P/E -6.80
P/E Growth Ratio
P/BV 3.61
P/S 32.14
P/CF -7.47

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2014-01-16
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.